RCEL logo

AVITA MEDICAL INC

RCELNASDAQ
πŸ† #3214 by market capUS Equity
$339.01β–Ό $14.20 (βˆ’4.19%)
Simulated price
πŸ””
Track RCEL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 4.2%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$366M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+1.0%
Slowing
πŸ“ŠGross Margin
82.1%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
4.8x
Fair
Otter Score
72
Fair
No chart data available for RCEL.

Trading Snapshot

Day Range
$334.96 – $341.70
52-Week Range
$3.22 – $12.23
Volume
$3.36B
Avg Volume
$2.64B
Shares Outstanding
30.8M
Next Earnings
Nov 18, 2026

Fundamentals Snapshot

Annual Revenue
$72M
Last Q Revenue
$22M
P/E Ratio
β€”
P/S Ratio
4.8x
EPS (TTM)
$-1.44
Dividend Yield
β€”
Dilution (1yr)
+16.2%

Why Investors Own RCEL

  • βœ“High-growth profile β€” revenue up +38.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 26% gross margin and 13% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RCEL logo

AVITA MEDICAL INC

RCEL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$72Mβ–² +11.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
82.1%β–Ό βˆ’4.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$43Mβ–Ό βˆ’24.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$33Mβ–Ό βˆ’43.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.4Mβ–² +16.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$36Mβ–Ό βˆ’$4M YoY
StockOtter Β· stockotter.space

About AVITA MEDICAL INC

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cmΒ²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
72/100

Analyst Price Target

β“˜
Average Target
$379.36
β–² +11.9% Upside
High Target$414.18
Low Target$293.71
Based on 13 analysts

Latest News & Updates